Nurix Therapeutics, Inc.
For the period ended Aug 31, 2025. Filed Oct 9, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Aug 31, 2025 · Filed Oct 9, 2025
NRIX$16.14+5.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations
(in thousands, except share and per share amounts)
| Three Months EndedAugust 31, | Nine Months EndedAugust 31, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenue: | ||||
| Collaboration revenue | $7,894 | $12,588 | $40,403 | $41,265 |
| License revenue | — | — | 30,000 | — |
| Total revenue | 7,894 | 12,588 | 70,403 | 41,265 |
| Operating expenses: | ||||
| Research and development | 86,120 | 55,481 | 233,879 | 154,408 |
| General and administrative | 13,159 | 11,718 | 39,095 | 35,227 |
| Total operating expenses | 99,279 | 67,199 | 272,974 | 189,635 |
| Loss from operations | (91,385) | (54,611) | (202,571) | (148,370) |
| Interest and other income, net | 4,964 | 5,737 | 17,095 | 13,612 |
| Loss before income taxes | (86,421) | (48,874) | (185,476) | (134,758) |
| Provision for income taxes | — | 82 | 760 | 262 |
| Net loss | $(86,421) | $(48,956) | $(186,236) | $(135,020) |
| Net loss per share, basic and diluted | $(1.03) | $(0.67) | $(2.22) | $(2.13) |
| Weighted-average number of shares outstanding, basic and diluted | 84,159,336 | 72,779,381 | 83,869,469 | 63,384,174 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.